Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improve in vitro dissolution and in vivo oral absorption

References

• Lipinski CA. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods, 44:235–249.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 46:3–26.
   PubMed Web of Science ®Google Scholar
• Lipinski CA. (2002). Poorly aqueous solubility: An industry wide problem in drug discovery. Am Pharm Rev, 5:82–85.
   Google Scholar
• Liversidge GG, Cundy KC. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91–97.
   Web of Science ®Google Scholar
• Jan M, Georgr A, Herberk P, Rainer HM. (2004). Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm, 58:615–619.
   PubMed Web of Science ®Google Scholar
• Rogers TL, Gillespie IB, Hitt JE, Fransen KL, Crowl CA, Tucker CJ et al. (2004). Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm Res, 21:2048–2057.
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113–120.
   PubMed Web of Science ®Google Scholar
• Mittapalli PK, Yamasani MR, Shashank A. (2007). Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Current Nanoscience, 3:191–194.
   Web of Science ®Google Scholar
• Mittapalli PK, Yamasani MR, Shashank A. (2008). Formulation of nanosuspensions of albendazole for oral administration. Current Nanoscience, 4:53–58.
   Web of Science ®Google Scholar
• Onoue S, Sato H, Ogawa K, Kawabata Y, Mizumoto T, Yuminoki K et al. (2010). Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach. Int J Pharm, 399:94–101.
   PubMed Web of Science ®Google Scholar
• Niwa T, Miura S, Danjo K. (2011). Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies - Development of particle design method. Int J Pharm, 405:218–227.
   PubMed Web of Science ®Google Scholar
• Inkyo M, Tahara T. (2004). Dispersion of agglomerated nanoparticles by fine beads mill. J Soc Powder Technol, Japan, 41:578–585.
   Google Scholar
• Inkyo M. (2005). Dispersion Technology Book. Tokyo: Johokiko Co. Ltd. pp 73–86.
   Google Scholar
• Braun A, Zhang S, Miettinen HE, Ebrahim S, Holm TM, Vasile E et al. (2003). Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci USA, 100:7283–7288.
   PubMed Web of Science ®Google Scholar
• Hong SC, Zhao SP, Liu Q, Wu ZH. (2008). Effect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits. Int J Cardiol, 123:180–182.
   PubMed Web of Science ®Google Scholar
• Heeg JF, Hiser MF, Satonin DK, Rose JQ. (1984). Pharmacokinetics of probucol in male rats. J Pharm Sci, 73:1758–1763.
   PubMed Web of Science ®Google Scholar
• Shudo J, Pongpeerapat A, Wanawongthai C, Moribe K, Yamamoto K. (2008). In vivo assessment of oral administration of probucol nanoparticles in rats. Biol Pharm Bull, 31:321–325.
   PubMed Web of Science ®Google Scholar
• Yagi N, Terashima Y, Kenmotsu H, Sekikawa H. (1996). Dissolution behavior of probucol from solid dispersion systems of probucolpolyvinylpyrrolidone. Chem Pharm Bull, 44:241–244.
   Web of Science ®Google Scholar
• Betge S, Lutz K, Roskos M, Figulla HR. (2007). Oral treatment with probucol in a pharmacological dose has no beneficial effects on mortality in chronic ischemic heart failure after large myocardial infarction in rats. Eur J Pharmacol, 558:119–127.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S. (2009). Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders. Chem Pharm Bull, 57:1050–1057.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S. (2010). Evaluation of in vitro dissolution and in vivo oral absorption of drug nanopowders prepared by novel wet-milling equipment. Current Nano Science, 6:571–576.
   Web of Science ®Google Scholar
• Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. (1998). Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res, 15:698–705.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Reppas C. (2000). In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11 Suppl 2:S73–S80.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Alakhov VY. (2002). Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst, 19:1–72.
   PubMed Web of Science ®Google Scholar
• Rahme K, Oberdisse J, Schweins R, Gaillard C, Marty JD, Mingotaud C et al. (2008). Pluronics-stabilized gold nanoparticles: Investigation of the structure of the polymer-particle hybrid. Chemphyschem, 9:2230–2236.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, Zheng T, Wang S. (2007). Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm, 33:1332–1339.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chai G, Zeng X, He H, Xu H, Tang X. (2010). Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. Drug Dev Ind Pharm, 36:1054–1063.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. (2009). Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm, 35:1479–1486.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kathan K, Saad W, Prud’homme RK. (2007). Ostwald ripening of β-carotene nanoparticles. Phys Rev Lett, 98:036102.
   PubMed Web of Science ®Google Scholar
• Cartwright JH, Piro O, Tuval I. (2009). Ostwald ripening, chiral crystallization, and the common-ancestor effect. Drug Dev Ind Pharm, 35:1479–1486.
   PubMedGoogle Scholar
• Bastús NG, Comenge J, Puntes V. (2011). Kinetically controlled seeded growth synthesis of citrate-stabilized gold nanoparticles of up to 200 nm: Size focusing versus Ostwald ripening. Langmuir, 27:11098–11105.
   PubMed Web of Science ®Google Scholar
• Wu W, Zhang S, Zhou J, Xiao X, Ren F, Jiang C. (2011). Controlled synthesis of monodisperse sub-100 nm hollow SnO2 nanospheres: A template- and surfactant-free solution-phase route, the growth mechanism, optical properties, and application as a photocatalyst. Chemistry, 17:9708–9719.
   PubMed Web of Science ®Google Scholar
• Kattige A, Rowley G. (2006). The effect of poloxamer viscosity on liquid-filling of solid dispersions in hard gelatin capsules. Drug Dev Ind Pharm, 32:981–990.
   PubMed Web of Science ®Google Scholar
• Brochure Gelucire® 44/14. 1st Edition. Gattefosse S.A. (1999).
   Google Scholar
• Brochure Gelucire® 50/13. 1st Edition. Gattefosse. S.A. (1999).
   Google Scholar
• Brochure Eastman Vitamin E TPGS NF. Eastman Chemical Company. (1998).
   Google Scholar
• Kim KR, Ahn KY, Park JS, Lee KE, Jeon H, Lee J. (2011). Lyophilization and enhanced stability of fluorescent protein nanoparticles. Biochem Biophys Res Commun, 408:225–229.
   PubMed Web of Science ®Google Scholar
• Hafner A, Dürrigl M, Pepic I, Filipovic-Grcic J. (2011). Short- and long-term stability of lyophilised melatonin-loaded lecithin/chitosan nanoparticles. Chem Pharm Bull, 59:1117–1123.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev, 58:1688–1713.
   PubMed Web of Science ®Google Scholar
• Cho E, Cho W, Cha KH, Park J, Kim MS, Kim JS, Park HJ, Hwang SJ. (2010). Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives. Int J Pharm, 396:91–98.
   PubMed Web of Science ®Google Scholar
• Jarmer DJ, Lengsfeld CS, Anseth KS, Randolph TW. (2005). Supercritical fluid crystallization of griseofulvin: Crystal habit modification with a selective growth inhibitor. J Pharm Sci, 94:2688–2702.
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Phillips CP, Cundy KC. (1994). US patent US 5302401 (1994).
   Google Scholar
• Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, Van den Mooter G. (2007). Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm, 338:198–206.
   PubMed Web of Science ®Google Scholar
• Konan YN, Gurny R, Allémann E. (2002). Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 233:239–252.
   PubMed Web of Science ®Google Scholar
• Lindahl A, Ungell AL, Knutson L, Lennernäs H. (1997). Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res, 14:497–502.
   PubMed Web of Science ®Google Scholar
• Vertzoni M, Fotaki N, Kostewicz E, Stippler E, Leuner C, Nicolaides E et al. (2004). Dissolution media simulating the intralumenal composition of the small intestine: Physiological issues and practical aspects. J Pharm Pharmacol, 56:453–462.
   PubMed Web of Science ®Google Scholar
• McConnell EL, Fadda HM, Basit AW. (2008). Gut instincts: Explorations in intestinal physiology and drug delivery. Int J Pharm, 364:213–226.
   PubMed Web of Science ®Google Scholar
• Overhoff KA, McConville JT, Yang W, Johnston KP, Peters JI, Williams RO 3rd. (2008). Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res, 25:167–175.
   PubMed Web of Science ®Google Scholar
• Pandit N, Trygstad T, Croy S, Bohorquez M, Koch C. (2000). Effect of Salts on the Micellization, Clouding, and Solubilization Behavior of Pluronic F127 Solutions. J Colloid Interface Sci, 222:213–220.
   PubMed Web of Science ®Google Scholar
• Khutoryanskiy VV, Mun GA, Nurkeeva ZS, Dubolazov AV. (2004). pH and salt effects on interpolymer complexation via hydrogen bonding in aqueous solutions. Polym Int, 53:1382–1387.
   Web of Science ®Google Scholar
• Comba S, Sethi R. (2009). Stabilization of highly concentrated suspensions of iron nanoparticles using shear-thinning gels of xanthan gum. Water Res, 43:3717–3726.
   PubMed Web of Science ®Google Scholar
• Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y et al. (2006). Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res, 23:1144–1156.
   PubMed Web of Science ®Google Scholar
• Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y et al. (2008). Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res, 25:2334–2344.
   PubMed Web of Science ®Google Scholar
• Takano R, Takata N, Saito R, Furumoto K, Higo S, Hayashi Y, Machida M, Aso Y, Yamashita S. (2010). Quantitative analysis of the effect of supersaturation on in vivo drug absorption. Mol Pharm, 7:1431–1440.
   PubMed Web of Science ®Google Scholar